Patient recruitment expert Ross Jackson talks about why this part of the clinical trials ecosystem is still a problem and offers up some solutions, specifically around digital/social media outreach.
In this on-demand webinar, industry experts Ken Getz and Jim Murphy provide insights into the anticipated trends within the clinical trial landscape for 2024. Gain a comprehensive understanding of the future direction of clinical trials and the latest developments.
The FDA's quality by design and risk-based monitoring messaging began more than 10 years ago with their guidance on RBM. 11 years, 5 total related key guidance documents, and 1 global pandemic later, why aren’t we moving forward at more than a snail’s pace?
Diversity in clinical trials is vital for advancing research and ensuring equitable care. Explore the significance of diversity, the DEPICT Act's role, and collaborative efforts to foster inclusivity.
The FDA recently issued a new draft guidance titled Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products. It represents a step forward in the journey toward increasing diversity in clinical trials and representation of the real-world populations who will use the products in studies.
This website uses cookies to ensure you get the best experience on our website. Learn more